Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Structure and assembly of pilotin-dependent and -independent secretins of the type II secretion system.

Howard SP, Estrozi LF, Bertrand Q, Contreras-Martel C, Strozen T, Job V, Martins A, Fenel D, Schoehn G, Dessen A.

PLoS Pathog. 2019 May 13;15(5):e1007731. doi: 10.1371/journal.ppat.1007731. eCollection 2019 May.

2.

Large volume re-irradiation for recurrent meningioma with pulsed reduced dose rate radiotherapy.

Witt JS, Musunuru HB, Bayliss RA, Howard SP.

J Neurooncol. 2019 Jan;141(1):103-109. doi: 10.1007/s11060-018-03011-z. Epub 2018 Nov 3.

PMID:
30392090
3.

Radiation treatment planning and delivery strategies for a pregnant brain tumor patient.

Labby ZE, Barraclough B, Bayliss RA, Besemer AE, Dunkerley DAP, Howard SP.

J Appl Clin Med Phys. 2018 Sep;19(5):368-374. doi: 10.1002/acm2.12262. Epub 2018 Jul 30.

4.

Bone marrow suppression as a complication of total skin helical tomotherapy in the treatment of mycosis fungoides.

Schaff EM, Rosenberg SA, Olson SJ, Howard SP, Bradley KA.

Radiat Oncol. 2018 Apr 13;13(1):67. doi: 10.1186/s13014-018-1013-2.

5.

Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database.

Blumenthal DT, Won M, Mehta MP, Gilbert MR, Brown PD, Bokstein F, Brachman DG, Werner-Wasik M, Hunter GK, Valeinis E, Hopkins K, Souhami L, Howard SP, Lieberman FS, Shrieve DC, Wendland MM, Robinson CG, Zhang P, Corn BW.

Neuro Oncol. 2018 Jun 18;20(7):966-974. doi: 10.1093/neuonc/noy017.

6.

Primary intracranial leiomyosarcoma in an immunocompetent patient: Case report and review of the literature.

Gallagher SJ, Rosenberg SA, Francis D, Salamat S, Howard SP, Kimple RJ.

Clin Neurol Neurosurg. 2018 Feb;165:76-80. doi: 10.1016/j.clineuro.2017.12.014. Epub 2018 Jan 6. Review.

PMID:
29324399
7.

Familial Trigeminal Neuralgia Treated with Stereotactic Radiosurgery: A Case Report and Literature Review.

Denu RA, Rosenberg SA, Howard SP.

J Radiat Oncol. 2017 Jun;6(2):149-152. doi: 10.1007/s13566-017-0300-0. Epub 2017 Mar 20.

8.

Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525.

Shi W, Scannell Bryan M, Gilbert MR, Mehta MP, Blumenthal DT, Brown PD, Valeinis E, Hopkins K, Souhami L, Andrews DW, Tzuk-Shina T, Howard SP, Youssef EF, Lessard N, Dignam JJ, Werner-Wasik M.

Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):38-44. doi: 10.1016/j.ijrobp.2017.08.038. Epub 2017 Sep 4.

9.

The evolving role for re-irradiation in the management of recurrent grade 4 glioma.

Howard SP, Krauze A, Chan MD, Tsien C, Tomé WA.

J Neurooncol. 2017 Sep;134(3):523-530. doi: 10.1007/s11060-017-2392-1. Epub 2017 Apr 6. Review.

PMID:
28386661
10.

Alterations in Peptidoglycan Cross-Linking Suppress the Secretin Assembly Defect Caused by Mutation of GspA in the Type II Secretion System.

Vanderlinde EM, Strozen TG, Hernández SB, Cava F, Howard SP.

J Bacteriol. 2017 Mar 28;199(8). pii: e00617-16. doi: 10.1128/JB.00617-16. Print 2017 Apr 15.

11.

Karenitecin (bnp1350) and flavopridol as radiosensitizers in malignant glioma.

Rajesh D, Robins HI, Howard SP.

J Neurol Neuromedicine. 2016;1(6):1-10.

12.

Comment on "A Novel Thymoma-Associated Immunodeficiency with Increased Naive T Cells and Reduced CD247 Expression".

Welsh JS, Howard SP.

J Immunol. 2015 Oct 15;195(8):3505. doi: 10.4049/jimmunol.1501667. No abstract available.

13.

Persistent Activation of the Innate Immune Response in Adult Drosophila Following Radiation Exposure During Larval Development.

Sudmeier LJ, Samudrala SS, Howard SP, Ganetzky B.

G3 (Bethesda). 2015 Sep 1;5(11):2299-306. doi: 10.1534/g3.115.021782.

14.

A Drosophila model to investigate the neurotoxic side effects of radiation exposure.

Sudmeier LJ, Howard SP, Ganetzky B.

Dis Model Mech. 2015 Jul 1;8(7):669-77. doi: 10.1242/dmm.019786.

15.

Assembly of the type two secretion system in Aeromonas hydrophila involves direct interaction between the periplasmic domains of the assembly factor ExeB and the secretin ExeD.

Vanderlinde EM, Zhong S, Li G, Martynowski D, Grochulski P, Howard SP.

PLoS One. 2014 Jul 15;9(7):e102038. doi: 10.1371/journal.pone.0102038. eCollection 2014.

16.

Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM).

Krauze AV, Won M, Graves C, Corn BW, Muanza TM, Howard SP, Mahadevan A, Schultz CJ, Haas ML, Mehta MP, Camphausen KA.

Biomark Res. 2013 Oct 31;1(1):29. doi: 10.1186/2050-7771-1-29.

17.

Wide-field pulsed reduced dose rate radiotherapy (PRDR) for recurrent ependymoma in pediatric and young adult patients.

Mohindra P, Robins HI, Tomé WA, Hayes L, Howard SP.

Anticancer Res. 2013 Jun;33(6):2611-8.

PMID:
23749916
18.

YghG (GspSβ) is a novel pilot protein required for localization of the GspSβ type II secretion system secretin of enterotoxigenic Escherichia coli.

Strozen TG, Li G, Howard SP.

Infect Immun. 2012 Aug;80(8):2608-22. doi: 10.1128/IAI.06394-11. Epub 2012 May 14.

19.

Involvement of the GspAB complex in assembly of the type II secretion system secretin of Aeromonas and Vibrio species.

Strozen TG, Stanley H, Gu Y, Boyd J, Bagdasarian M, Sandkvist M, Howard SP.

J Bacteriol. 2011 May;193(9):2322-31. doi: 10.1128/JB.01413-10. Epub 2011 Mar 4.

20.

Assembly of the type II secretion system: identification of ExeA residues critical for peptidoglycan binding and secretin multimerization.

Li G, Miller A, Bull H, Howard SP.

J Bacteriol. 2011 Jan;193(1):197-204. doi: 10.1128/JB.00882-10. Epub 2010 Oct 22.

21.

Treatment planning for pulsed reduced dose-rate radiotherapy in helical tomotherapy.

Rong Y, Paliwal B, Howard SP, Welsh J.

Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):934-42. doi: 10.1016/j.ijrobp.2010.05.055. Epub 2010 Sep 29.

PMID:
20884127
22.

Reirradiation of glioblastoma through the use of a reduced dose rate on a tomotherapy unit.

Rasmussen KH, Hardcastle N, Howard SP, Tomé WA.

Technol Cancer Res Treat. 2010 Aug;9(4):399-406.

23.

Reirradiation of large-volume recurrent glioma with pulsed reduced-dose-rate radiotherapy.

Adkison JB, Tomé W, Seo S, Richards GM, Robins HI, Rassmussen K, Welsh JS, Mahler PA, Howard SP.

Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):835-41. doi: 10.1016/j.ijrobp.2009.11.058. Epub 2010 May 14.

PMID:
20472350
24.

ExeA binds to peptidoglycan and forms a multimer for assembly of the type II secretion apparatus in Aeromonas hydrophila.

Li G, Howard SP.

Mol Microbiol. 2010 May;76(3):772-81. doi: 10.1111/j.1365-2958.2010.07138.x. Epub 2010 Mar 25.

25.
26.

Pulsed reduced dose-rate radiotherapy: a novel locoregional retreatment strategy for breast cancer recurrence in the previously irradiated chest wall, axilla, or supraclavicular region.

Richards GM, Tomé WA, Robins HI, Stewart JA, Welsh JS, Mahler PA, Howard SP.

Breast Cancer Res Treat. 2009 Mar;114(2):307-13. doi: 10.1007/s10549-008-9995-3. Epub 2008 Apr 4.

PMID:
18389365
27.

Systemic iodine 125 activity after GliaSite brachytherapy: safety considerations.

Adkison JB, Thomadsen B, Howard SP.

Brachytherapy. 2008 Jan-Mar;7(1):43-6. doi: 10.1016/j.brachy.2007.11.001. Epub 2008 Jan 16.

PMID:
18201938
28.
29.

Pulsed reduced dose-rate radiotherapy: case report : a novel re-treatment strategy in the management of recurrent glioblastoma multiforme.

Cannon GM, Tomé WA, Robins HI, Howard SP.

J Neurooncol. 2007 Jul;83(3):307-11. Epub 2007 Jan 25.

PMID:
17252184
30.
31.

Interactions between peptidoglycan and the ExeAB complex during assembly of the type II secretin of Aeromonas hydrophila.

Howard SP, Gebhart C, Langen GR, Li G, Strozen TG.

Mol Microbiol. 2006 Feb;59(3):1062-72.

32.

Motexafin-gadolinium taken up in vitro by at least 90% of glioblastoma cell nuclei.

De Stasio G, Rajesh D, Ford JM, Daniels MJ, Erhardt RJ, Frazer BH, Tyliszczak T, Gilles MK, Conhaim RL, Howard SP, Fowler JF, Estève F, Mehta MP.

Clin Cancer Res. 2006 Jan 1;12(1):206-13.

33.

Sm-153 EDTMP for recurrent metastatic osteosarcoma.

Welsh JS, Thurman SA, Borzillary S, Schwartz CL, Howard SP.

Clin Adv Hematol Oncol. 2003 Mar;1(3):181-3; discussion 183. No abstract available.

PMID:
16224400
36.

Identification and characterization of putative virulence genes and gene clusters in Aeromonas hydrophila PPD134/91.

Yu HB, Zhang YL, Lau YL, Yao F, Vilches S, Merino S, Tomas JM, Howard SP, Leung KY.

Appl Environ Microbiol. 2005 Aug;71(8):4469-77.

37.

Are gadolinium contrast agents suitable for gadolinium neutron capture therapy?

De Stasio G, Rajesh D, Casalbore P, Daniels MJ, Erhardt RJ, Frazer BH, Wiese LM, Richter KL, Sonderegger BR, Gilbert B, Schaub S, Cannara RJ, Crawford JF, Gilles MK, Tyliszczak T, Fowler JF, Larocca LM, Howard SP, Mercanti D, Mehta MP, Pallini R.

Neurol Res. 2005 Jun;27(4):387-98.

PMID:
15949236
38.

Thymoma and multiple malignancies: a case of five synchronous neoplasms and literature review.

Welsh JS, Thurman SA, Howard SP.

Clin Med Res. 2003 Jul;1(3):227-32. Review.

39.

Walking forward: the South Dakota Native American project.

Petereit DG, Rogers D, Burhansstipanov L, Kaur J, Govern F, Howard SP, Osburn CH, Coleman CN, Fowler JF, Chappell R, Mehta MP.

J Cancer Educ. 2005 Spring;20(1 Suppl):65-70.

PMID:
15916524
40.

Precautions in the use of intensity-modulated radiation therapy.

Welsh JS, Limmer JP, Howard SP, Diamond D, Harari PM, Tome W.

Technol Cancer Res Treat. 2005 Apr;4(2):203-10. Review.

PMID:
15773789
41.

Increasing access to clinical cancer trials and emerging technologies for minority populations: the Native American Project.

Petereit DG, Rogers D, Govern F, Coleman N, Osburn CH, Howard SP, Kaur J, Burhansstipanov L, Fowler CJ, Chappell R, Mehta MP.

J Clin Oncol. 2004 Nov 15;22(22):4452-5. No abstract available.

PMID:
15542797
42.

Crystal structure of a 92-residue C-terminal fragment of TonB from Escherichia coli reveals significant conformational changes compared to structures of smaller TonB fragments.

Ködding J, Killig F, Polzer P, Howard SP, Diederichs K, Welte W.

J Biol Chem. 2005 Jan 28;280(4):3022-8. Epub 2004 Nov 2.

43.

Non-Hodgkin's lymphoma presenting as a pelvic mass with elevated CA-125.

Allen GW, Forouzannia A, Bailey HH, Howard SP.

Gynecol Oncol. 2004 Sep;94(3):811-3.

PMID:
15350377
44.

Crystallization and preliminary X-ray analysis of a C-terminal TonB fragment from Escherichia coli.

Koedding J, Polzer P, Killig F, Howard SP, Gerber K, Seige P, Diederichs K, Welte W.

Acta Crystallogr D Biol Crystallogr. 2004 Jul;60(Pt 7):1281-3. Epub 2004 Jun 22.

PMID:
15213392
45.

Loss of biological effect in prolonged fraction delivery.

Fowler JF, Welsh JS, Howard SP.

Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):242-9. Review.

PMID:
15093921
46.

In vivo evidence for TonB dimerization.

Sauter A, Howard SP, Braun V.

J Bacteriol. 2003 Oct;185(19):5747-54.

47.

Dose rate in external beam radiotherapy for prostate cancer: an overlooked confounding variable?

Welsh JS, Howard SP, Fowler JF.

Urology. 2003 Aug;62(2):204-6. No abstract available.

PMID:
12893319
48.
49.

Perillyl alcohol as a radio-/chemosensitizer in malignant glioma.

Rajesh D, Stenzel RA, Howard SP.

J Biol Chem. 2003 Sep 19;278(38):35968-78. Epub 2003 Jun 12.

50.

Expression of the ExeAB complex of Aeromonas hydrophila is required for the localization and assembly of the ExeD secretion port multimer.

Ast VM, Schoenhofen IC, Langen GR, Stratilo CW, Chamberlain MD, Howard SP.

Mol Microbiol. 2002 Apr;44(1):217-31.

Supplemental Content

Loading ...
Support Center